Walder Wyss with Veraxa on merger with Voyager Acquisition Corp
Walder Wyss advised Zurich-based Veraxa Biotech on its merger with Voyager Acquisition Corp, a Cayman Islands publicly traded Special Purpose Acquisition Company (SPAC).
The context
The companies signed an agreement on 23 April 2025, with the closing planned for Q4 2025. Pursuant to the operation Veraxa values at up to USD 1.64 billion. Upon completion of the deal, Veraxa Biotech will become a Nasdaq-listed company.
The Walder Wyss team
Partners Marius Breier (tax, pictured left) and Thiemo Sturny (corporate/M&A, pictured right) led the Walder Wyss team on the matter, working alongside senior associate Martina Madonna-Quadri (corporate/M&A), partner Maurus Winzap (tax), associate Claude Schmid (tax), senior associate Erik Lanz (corporate/M&A) and senior associate Gustaf Heintz (employment).
